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ABSTRACT
Background. Reports on the risk factors of peritoneal
recurrence (PR) after liver resection for hepatocellular
carcinoma are lacking. We examined the risk factors of PR
after hepatectomy and the outcome of resected PR at our
institution.
Methods. We retrospectively reviewed the data from
1,222 patients who underwent hepatectomies for hepato-
cellular carcinoma in Samsung Medical Center from
January 2006 to August 2010. We identiﬁed patients with
PR and studied the risk factors and outcomes of resected
PR.
Results. The rate of PR was 3.0% (n = 36). The
mean ± SD age of patients was 54.0 ± 10.2 years. Among
those with PR, 23 patients (63.9%) had unresectable dis-
ease and 13 patients (36.1%) had resectable disease.
Multivariate analysis found that tumor size [50 mm,
presence of microvascular invasion, bile duct invasion, and
positive margins were signiﬁcant risk factors of PR after
liver resection. The median overall survival (OS) for
resectable PR was 33.0 (28.0–61.6) months compared to
14.0 (6.8–21.2) months for unresectable PR (P = 0.009).
Cox regression analysis demonstrated that resected PR
[hazard ratio (HR) 0.042, P = 0.001] and interval between
hepatectomy and PR ([6months) (HR 0.195, P = 0.016)
were positive prognostic factors for OS, while alfa-feto-
protein [200 ng/dl at detection of PR (HR 11.321,
P = 0.015) and serosal involvement of primary hepato-
cellular carcinoma (HR 25.616, P = 0.007) were negative
prognostic factors for OS.
Conclusions. We found that tumor size[50 mm, presence
of microvascular invasion, bile duct invasion, and positive
resection margins were signiﬁcant risk factors of PR after
liver resection. Selected patients with resected PR had
signiﬁcantly better OS.
Hepatocellular carcinoma (HCC) is a highly prevalent
malignancy, affecting approximately over half a million
people worldwide.
1 In Korea, HCC is the third leading
malignancy after stomach and lung cancers. According to
2005statistics,theage-adjustedincidenceofprimaryHCCis
44.9 per 100,000 men.
2,3 Chronic hepatitis B is endemic in
Korea, representing the most important risk factor, consti-
tuting approximately 70% of all cases of HCC.
4,5 Although
liver transplantation for HCC has altered the natural history
of this disease, liver resection remains one of the main
treatment modalities that provides good outcome.
6–10
Peritoneal implantation in HCC is uncommon, with
reported incidences ranging 2–16%.
11–14 Generally, perito-
neal recurrence (PR) in HCC was considered to be an
incurable terminal disease. Patients are rarely suitable for
surgical resection of PR in HCC. Reports on the long-term
outcome PR resection are lacking in the literature. A few
anecdotal case reports have documented satisfactory out-
come after surgical resection of PR in HCC.
15–22 One of the
largestserieswasareportfromaTaiwanesecenter,reporting
a median survival of 16 months in patients who underwent
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23 However, studies on
the risk factors of PR and resected peritoneal lesions remain
rare in the literature. There is a lack of recommendations in
the management of PR in HCC after resection.
Selected patients with PR after liver resection underwent
resection of the peritoneal lesions at our institution. Our
primary aim was to investigate the risk factors inﬂuencing
PR in HCC after liver resection. A secondary aim was to
determine the predictive factors for resected PR after liver
resection and its long-term outcome. From this informa-
tion, we drew up guidelines for resection of PR in HCC
after hepatectomy.
PATIENTS AND METHODS
We performed retrospective data collection of all
patients who underwent liver resection for HCC at Sam-
sung Medical Center, South Korea, from January 2006 to
September 2010. After excluding patients who were lost to
follow-up, 1,222 cases were suitable for analysis. During
the process of data collection, we identiﬁed patients with
PR documented by imaging studies and those who under-
went resection of PR.
Demographic details (including the causative factor of
HCC) and prehepatectomy tumor marker levels [alfa-feto-
protein (AFP) and protein induced by vitamin K absence or
antagonist-II (PIVKA-II)] and other treatment modalities
(e.g., radiofrequency ablation, transarterial chemoemboliza-
tion) were collected from patients’ electronic medical
records. Surveillance of patients with HCC after liver resec-
tion was performed at 3 month intervals for the ﬁrst 2 years
andthenevery4–6 monthsthereafter.Duringthevisit,tumor
markers such as AFP and PIVKA-II were assayed. Elevated
tumor markers prompted the suspicion of tumor recurrence,
and further investigations were performed to ascertain the
diagnosis. Options of the radiologic imaging included com-
puted tomographic scan of the abdomen and pelvis (with
computed tomography of the thorax), magnetic resonance
imaging, and/or positron emission tomography scan.
The aim of the investigations was twofold. First, the
investigations would help determine the locations of recur-
rences,numberoflesions,andwhethertheywereresectable.
Second, the presence of extra-abdominal metastases that
would preclude further curative resection would be ascer-
tained. In the absence of other systemic metastasis or
inoperableintrahepaticrecurrencesofHCC,iftheperitoneal
lesions were resectable and without compromising essential
anatomic structures such as major vasculature, surgical
resection would be offered to the patient.
After ascertaining that PRs were suitable for resection,
the next step was to ensure that the selected patients were ﬁt
to undergo the operation. Careful preoperative assessment
was carried out. At the operation, a midline incision was
made to facilitate exploratory laparotomy. Careful adhesi-
olysis was performed to avoid enterotomy when adhesion
was encountered. Locations and number of lesions were
conﬁrmed with the preoperative scans. Resection of the
peritoneal lesions was carefully performed to ensure ade-
quate surgical margin. En-bloc resection of the lesion, along
with its surrounding structures, such as the small bowel or
the cuff of diaphragm, was occasionally required. In situa-
tionswherethemalignantnatureofthelesionwasuncertain,
excision for frozen section histology was performed intra-
operatively. Careful hemostasis and selective placement of
abdominal drains at surgical sites were performed.
Postoperative histologic assessment and reporting
included maximum tumor diameter, Edmonson grade of
HCC, microvascular invasion (MVI), portal vein/hepatic
vein invasion, bile duct invasion, serosal involvement,
intrahepatic metastasis, multicentric occurrence of HCC,
and resection margin. tumor, node, metastasis system
staging was performed in accordance with the American
Joint Committee on Cancer (seventh edition) staging sys-
tem.
24 R0 resection status was deﬁned as the presence of
microscopic tumor [1 mm from the resection margin.
There was no patient with R2 resection in this cohort.
Detailed information of patients who were identiﬁed to
have PR was recorded. The interval from hepatectomy to
PR was documented. For those who developed unresec-
table PR (commonly as a result of concurrent systemic
metastasis to other sites such as lung and bone, or unre-
sectable intrahepatic recurrence), radiologic information on
TABLE 1 Pattern of distribution of PR in the study cohort (n = 36)
Distribution Value
Location of PR
Omentum 17 (47.2%)
Posterior peritoneum
a 11 (30.6%)
Anterior peritoneum
b/abdominal wall 4 (11.1%)
Combination 4 (11.1%)
Posterior peritoneum with omental nodules 3 (8.3%)
Posterior peritoneum with chest wall 1 (2.8%)
No. of lesions
Single peritoneal lesion 13 (36.1%)
Multiple peritoneal lesions 23 (63.9%)
Median no. of lesions 2.0 (1.0–7.0)
Size of lesion or lesions (mm)
Median total size 48.5 (10.0–255.0)
Median largest size 25.5 (4.0–140.0)
a Posterior peritoneum included patients with PR located on dia-
phragmatic surface, posterior peritoneal lining near the right renal bed
and posterior abdominal wall next to the chest wall
b Anterior peritoneum included anterior abdominal wall and 1 patient
with tumor seeding on the serosa of sigmoid colon
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Parameter All NPR group PR group P
(n = 1222) (n = 1186) (n = 36)
Age (year), mean ± SD 54.0 ± 10.2 54.0 ± 10.2 51.0 ± 10.3 0.545
Gender
Male 977 (80.0%) 946 (79.7%) 31 (86.1%) 0.349
Female 245 (20.0%) 240 (20.2%) 5 (13.9%)
Cause of HCC
Chronic hepatitis B 940 (78.2%) 913 (78.4%) 26 (72.2%) 0.883
Chronic hepatitis C 62 (5.2%) 60 (5.1%) 2 (5.6%)
Other (alcoholic liver disease, etc.) 200 (21.5%) 192 (16.5%) 8 (22.2%)
History of ruptured HCC 14 (1.2%) 12 (1.0%) 2 (5.6%) 0.012*
Treatment before hepatectomy 198 (16.2%) 189 (15.9%) 9 (25.0%) 0.426
TACE 165 (83.3%) 158 (83.6%) 7 (77.8%) 0.879
RFA 18 (9.1%) 17 (9.0%) 1 (11.1%)
Both RFA and TACE 15 (7.6%) 14 (7.4%) 1 (11.1%)
Method of surgical access
Open 1143 (93.8%) 1110 (93.8%) 33 (91.7%) 0.138
Laparoscopic 70 (5.7%) 68 (5.7%) 2 (5.6%)
Laparoscopic converted to open 6 (0.5%) 5 (0.4%) 1 (2.8%)
Types of hepatectomy
Nonanatomic resection 573 (46.9%) 562 (47.4%) 11 (30.6%) 0.046*
Anatomic resection 649 (53.1%) 624 (52.6%) 25 (69.4%)
Right hemihepatectomy 251 (20.5%) 238 (20.1%) 13 (36.1%) 0.051
Left hemihepatectomy 3 (0.2%) 2 (0.2%) 1 (2.8%)
Posterior sectionectomy 125 (10.2%) 121 (10.2%) 4 (11.1%)
Anterior sectionectomy 21 (1.7%) 20 (1.7%) 1 (2.8%)
Extended right hepatectomy 30 (2.5%) 29 (2.4%) 1 (2.8%)
Extended left hepatectomy 20 (1.6%) 20 (1.7%) 0 (0.0%)
Left lateral sectionectomy 137 (11.2%) 134 (11.3%) 3 (8.3%)
Anatomic monosegmentectomy 13 (1.1%) 13 (1.1%) 0 (0.0%)
Central hepatectomy 49 (4.0%) 47 (4.0%) 2 (5.6%)
Bisegmentectomy 67 (5.5%) 65 (5.5%) 2 (5.6%)
Subsegmentectomy 506 (41.4%) 497 (41.9%) 9 (25.0%)
Preoperative blood parameters
Prehepatectomy AFP level, mean ± SD 5759.3 ± 64351.8 5391.8 ± 64691.7 17785.8 ± 51292.2 0.186
AFP B 400 ng/ml 922 (75.9%) 898 (76.2%) 24 (66.7%0 0.189
AFP[400 ng/ml 293 (24.1%) 281 (23.8%) 12 (33.3%)
Prehepatectomy PIVKA-II level, mean ± SD 209.3 ± 306.2 209.8 ± 307.2 192.5 ± 267.8 0.888
Size of HCC at hepatectomy, mm, median (range) 35.0 (2.0–210.0) 35.0 (2.0–210.0) 45.5 (13.0–170.0) 0.001*
Stratiﬁcation of size of HCC
Tumor B 50 mm 892 (73.0%) 871 (73.4%) 21 (58.3%) 0.002*
Tumor[50 mm 330 (27.0%) 315 (26.6%) 15 (41.7%)
Edmonson grade
I and II 1095 (91.6%) 1064 (91.5%) 31 (93.9%) 0.617
III and IV 101 (8.4%) 99 (8.5%) 2 (6.1%)
T stage of HCC
T1 and T2 963 (80.8%) 943 (81.3%) 20 (62.5%) 0.008*
T3 and T4 229 (19.2%) 217 (19.7%) 12 (37.5%)
2248 A. W. C. Kow et al.the number, size, and site of peritoneal lesions was mea-
sured from the scan. For patients who underwent resection
of PR, the operative and histologic data (including number
and size of lesions, as well as the location of lesions) were
clearly documented. Preoperative imaging ﬁndings on the
number, size, and site of peritoneal lesions were also
measured from the scan to allow comparison with unre-
sectable PRs. Information on subsequent recurrence of
peritoneal lesions and other sites of recurrence in this group
of patients was also recorded. Overall survival (OS) was
analyzed as the time from the date of hepatectomy until the
date of death (i.e., death from all causes, including dead of
disease and dead of other causes), whichever occurred ﬁrst.
Patients lost to follow-up or for whom the event of interest
had yet been observed were censored at the date last known
to be alive.
A total of 1,222 patients who underwent liver resection
for HCC during the study duration were accrued. We
studied the different parameters between two groups of
patients with and without PR after liver resection. We
classiﬁed the patients into those without PR (NPR) and
those with PR. Further analysis of resected and unresec-
table PR was performed.
Data were analyzed by SPSS software, version 17.0
(SPSS, Chicago, IL). Statistical signiﬁcance was set at a
P value of\0.05. The v
2 test was used in cross-tabulation
of nominal data. Student’s t test was performed for para-
metric continuous variables, and the Mann-Whitney U test
was used for nonparametric continuous variables. Logistic
and linear regression analyses were used to investigate the
predictors of PR. Kaplan-Meier analysis was used to depict
the OS and difference in survival between study groups.
RESULTS
Distribution of Patients and Pattern of Distribution
of PR
The mean ± SD age of this cohort was 54.0 ±
10.2 years. There were 1,186 patients (97.0%) in the NPR
group and 36 patients (3.0%) in the PR group. Within the
PR group, 23 patients (63.9%) had unresectable PR, and
another 13 patients (36.1%) underwent resection of PR.
TABLE 3 Multivariate analysis for risk factors of peritoneal recur-
rence of HCC after hepatectomy by logistic regression
Independent risk factor for PR OR 95% CI P
Ruptured HCC 3.800 0.668–21.929 0.132
Anatomic vs. nonanatomic resection 2.375 0.212–1.107 0.123
Tumor[50 mm 1.368 1.023–3.112 0.032*
T stage of tumor (T1 and T2 vs. T3
and T4)
0.901 0.356–2.282 0.815
Positive resection margin 9.540 1.746–18.733 0.042*
Microvascular invasion 3.896 1.164–8.165 0.023*
Bile duct invasion 3.720 1.179–12.279 0.025*
Portal vein invasion 0.508 0.583–5.000 0.476
Serosal involvement 3.184 0.813–28.042 0.074
Totally necrotic nodule 0.596 0.316–24.602 0.440
OR odds ratio, CI conﬁdence interval
* Signiﬁcant at P\0.05
TABLE 2 continued
Parameter All NPR group PR group P
(n = 1222) (n = 1186) (n = 36)
Combined HCC and IHCC 38 (3.1%) 35 (3.0%) 3 (8.3%) 0.067
Invasion/involvement
Tumor capsule involvement 1024 (85.4%) 995 (85.4%) 29 (85.3%) 0.985
Microvascular invasion 645 (52.8%) 618 (52.1%) 27 (75.0%) 0.007*
Bile duct invasion 35 (2.9%) 31 (2.7%) 4 (11.8%) 0.002*
Portal vein invasion 90 (7.5%) 84 (7.2%) 6 (17.6%) 0.022*
Serosal involvement 15 (1.3%) 13 (1.1%) 2 (5.9%) 0.014*
Intrahepatic metastasis 165 (13.7%) 158 (13.5%) 7 (20.6%) 0.238
Multicentric occurrence 59 (4.9%) 58 (5.0%) 1 (2.9%) 0.590
Totally necrotic nodule 21 (1.7%) 18 (1.5%) 3 (8.3%) 0.002*
Resection margin, mm, median (range) 10.0 (0.0–80.0) 10.0 (0.0–80.0) 8.0 (0.0–45.0) 0.360
Resection
R0 1183 (97.7%) 1152 (98.0%) 31 (88.6%) \0.001*
R1 28 (2.3%) 24 (2.0%) 4 (11.4%)
TACE transarterial chemoembolization, RFA radiofrequency ablation, IHCC intrahepatic cholangiocacinoma
* Statistically signiﬁcant at P\0.05
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(1.0–102.0) months. The most common site of PR was at
the omentum (n = 17, 47.2%). One-third of patients had a
single lesion (n = 13, 36.1%). The median number of
lesions was 2.0 (1.0–7.0) (Table 1).
Analysis of Clinicopathologic Factors Inﬂuencing PR
The demographic data in the NPR and PR groups were
not statistically signiﬁcant. Nine patients (25%) in the PR
group received other treatments before hepatectomy,
compared to 189 patients (15.9%) in the NPR group (P =
0.426). There were signiﬁcantly more patients in the PR
group who had ruptured HCC (n = 2, 5.6%) before liver
resection compared to the NPR group (n = 12, 1.0%)
(P = 0.012). Slightly more than half (n = 624, 52.6%) of
the liver resections in the NPR group were anatomic
resections, compared to 69.4% (n = 25) in the PR group
(P = 0.046) (Table 2).
The median tumor size of HCC in the PR group was
45.5 (13.0–170.0) mm, signiﬁcantly larger by 10.5 mm
compared to the median tumor size of HCC in the NPR
group (median 35.0 mm, range 2.0–210.0 mm, P =
0.001). The proportion of tumors[50 mm in size in the PR
group was 41.7% (n = 15) compared to 26.6% (n = 315)
in the NPR group (P = 0.002). There was a signiﬁcantly
larger proportion of T3 and T4 tumors in the PR group
(n = 12, 37.5%) compared to the NPR group (n = 217,
18.7%) (P = 0.008). The rates of MVI (P = 0.007), bile
duct invasion (P = 0.002), portal vein/hepatic vein inva-
sion (P = 0.022), serosal involvement (P = 0.014), and
totally necrotic nodule (P = 0.002) in the PR group were
signiﬁcantly higher compared to the NPR group. Further-
more, there was a signiﬁcantly higher proportion of HCC
specimens with positive resection margin in the PR group
(n = 4, 11.4%) compared to the NPR group (n = 24,
2.0%) (P\0.001).
Multivariate Analysis for Risk Factors of PR
The above factors found to be statistically signiﬁcant on
univariate analysis were examined by multivariate analysis.
By means of logistic regression, we found that tumor size
[50 mm [odds ratio (OR) 1.368, P = 0.032], presence of
MVI (OR 3.896, P = 0.023), bile duct invasion (OR 3.720,
P = 0.025), and positive resection margins (OR 9.540,
P = 0.042) were signiﬁcant predictors of PR after liver
resection for HCC in this cohort (Table 3).
Information at Time of Detection of PR
Twenty-three patients (63.9%) had unresectable PR,
while another 13 patients (36.1%) underwent resection of
TABLE 4 Information at the time of detection of PR
Clinicopathologic
factors
Unresectable PR Resectable PR P
(n = 23) (n = 13)
Interval between
hepatectomy and
PR, mo, median
(range)
6.0 (1.0–43.0) 11.0
(1.0–102.0)
0.009*
Interval between hepatectomy and peritoneal
Recurrence
B6 month 13 (56.5%) 5 (38.4%) 0.080
[6 month 10 (43.4%) 8 (61.5%)
Tumor markers at PR
AFP level,
mean ± SD
16519.7 ± 45832.1 575.4 ± 1475.2 0.032*
AFT level
B200 ng/dl 13 (56.5) 10 (76.9) 0.221
[200 ng/dl 10 (43.5) 3 (23.1)
PIVKA-II level
Mean ± SD 407.0 ± 498.1 180.5 ± 348.8 0.034*
B200 mAU/ml 11 (55.0) 10 (83.3) 0.102
[200 mAU/ml 9 (45.0) 2 (16.7)
No. of peritoneal
lesions, median
(range)
2.0 (1.0–7.0) 1.0 (1.0–4.0) 0.044*
Single lesion 6 (26.1%) 7 (53.8%) 0.096
Multiple lesions 17 (73.9%) 6 (46.2%)
Size of largest peritoneal lesion
Median (range),
mm
24.0 (4.0–60.0) 35.0
(10.0–140.0)
0.070
B30 mm 16 (69.6) 7 (30.4) 0.069
[30 mm 5 (38.5) 8 (61.5)
Total size of peritoneal lesion
Median (range),
mm
47.0 (20.0–255) 60.0
(10.0–140.0)
0.499
B50 mm 14 (60.9) 9 (39.1) 0.196
[50 mm 5 (38.5) 8 (61.5)
Location of PR
Omentum 17 (73.9%) 0 (0.0%) \0.001*
Posterior
peritoneum
4 (17.4%) 7 (53.8%)
Anterior
peritoneal/
abdominal wall
2 (8.7%) 2 (15.4%)
Combination 0 (0.0%) 4 (30.8%)
Posterior
peritoneum with
omental nodules
– 3 (23.1%)
Posterior
peritoneum with
chest wall
– 1 (7.7%)
Omental seeding 17 (73.9%) 3 (23.1%) \0.003*
Other 6 (26.1%) 10 (76.9%)
* Statistically signiﬁcant at P\0.05
2250 A. W. C. Kow et al.PR. The median interval between hepatectomy and PR in
the resected group was 11.0 (range 1.0–102.0) months,
5.0 months longer than the unresectable group (median
6.0 months, range 1.0–43.0 months, P = 0.009). There
were almost 20% more patients with a disease-free interval
of [6 months in the resected PR group (61.5% in the
resected group vs. 43.4% in unresectable group,
P = 0.080) (Table 4).
At the time of detection of PR, the median number of
lesion in the unresectable group was 2.0 (range 1.0–7.0),
compared to 1.0 (range 1.0–4.0) in the resected group
(P = 0.044). Although we were unable to demonstrate
statistical signiﬁcance, the proportion of patients with
solitary lesions in the resectable group (n = 7, 53.8%) was
doubled that in the unresectable group (n = 6, 26.1%),
with close to three-quarters of patients in the unresectable
group having multiple peritoneal lesions at recurrence
(n = 17, 73.9%) (P = 0.096). In terms of location, the
most common site of peritoneal metastasis in patients with
unresectable PR was at the omentum (73.9%); posterior
peritoneal lining (including diaphragm) was the most
common site in resected PR (53.8%) (P\0.001).
Long-Term Outcome (Survival Analysis) of PR
The OS for patients in the NPR group was signiﬁcantly
better compared to that in the PR group (P\0.001). The
1-, 3-, and 5-year OS for the NPR group was 87.0, 76.0,
and 72.0%, respectively, compared to that in the PR group,
which was 48.0, 23.0, and 14.0%, respectively (Fig. 1a).
However, the median OS for resected PR was signiﬁ-
cantly longer (33.0 months) compared to patients with
unresectable PR (14.0 months) (P = 0.009) (Fig. 1b). The
1-, 3-, and 5-year OS of patients with resected PR was 71.0,
48.0, and 48.0%, compared to 30.0, 6.0, and 6.0%,
respectively, for patients with unresectable PR
(P\0.001). Figure 2a shows the OS for various groups of
recurrences in comparison with resected and unresectable
PR. Resected PR was found to have comparable OS
compared with patients with only intrahepatic HCC
recurrence (P = 0.340) (Fig. 2b) but was signiﬁcantly
better than patients with other types of nonintrahepatic
HCC recurrence (P = 0.008) (Fig. 2c).
Prognostic Factors of OS for Patients with PR
By univariate analysis, we found that resected PR (P =
0.005), prehepatectomy AFP[400 ng/dl (P = 0.008),
HCC size[50 mm (P = 0.023), higher Edmonson grade
(P = 0.033), serosal involvement (P = 0.002), interval
betweenhepatectomyandPR[6 months(P = 0.001),and
AFP at detection of PR[200 ng/dl (P = 0.008) were sig-
niﬁcant factors. The use of sorafenib was not found to have
any survival beneﬁt (P = 0.092) (Table 5).
By Cox regression analysis, we found that resected PR
[hazard ratio (HR) 0.042, P = 0.001] and an interval
between hepatectomy and PR of [6 months (HR 0.181,
P = 0.001) were positive predictors of OS in patients with
PR. On the other hand, serosal involvement at primary
HCC (HR 25.616, P = 0.007) and AFP at detection of PR
(HR 11.321, P = 0.010) had a signiﬁcant negative inﬂu-
ence on the survival of patients with PR.
Information on Resected PR
Eight patients (61.5%) with resected PR were still alive
at the study’s completion. Patients with fewer lesions and
long intervals between hepatectomy and PR had a much
better outcomes compared to those with numerous perito-
neal lesions. Five patients (38.4%) experienced recurrent
peritoneal lesions, but only one underwent further resec-
tion. Another patient had recurrence at the chest wall and
1.0
0.8
0.6
0.4
0.2
NPR group 
(without peritoneal recurrence, n = 1186)
PR group 
(with peritoneal recurrence, n = 36)
1-year
87.0%
48.0%
NPR group
PR group
3-year
Overall survival
Duration (months)
76.0%
23.0%
5-year
72.0%
14.0%
Peritoneal
recurrence
100 0
*P < 0.001
20 40 60 80
1.0
0.8
0.6
0.4
0.2
Irresectable peritoneal recurrence (n = 23)
Resectable peritoneal recurrence (n = 13)
Duration (months)
1-year
30.0%
81.0%
Irresectable PR
Resectable PR
3-year
Overall survival
6.0%
58.0%
5-year
6.0%
58.0%
Median (95% CI) [months]
14.0 (6.8–21.2)
33.0 (28.0–61.6)
Peritoneal
recurrence
100 0
Percentage of
survival (%)
b
*P = 0.005
20 40 60 80
Percentage of
survival (%)
a Logrank analysis of overall survival comparing between
patients with and without peritoneal recurrences
FIG. 1 a OS of HCC patients
comparing the NPR group and
the PR group after
hepatectomies at a tertiary
institution. b OS of patients with
resectable and unresectable PR
after hepatectomies for HCC
Peritoneal Recurrence in HCC 2251underwent resection. Three patients survived more than
5 years. All three of them also had a long interval between
hepatectomy and detection of PR (48, 52, and 102 months,
respectively) (Table 6). One of them has since died.
DISCUSSION
After resection, tumor recurrence rate is exceedingly
high in HCC, reaching about 70% at 5 years.
7,25–27 Most of
the recurrences occur within the liver. Common sites of
systemic metastasis of HCC after resection are lungs,
bones, and brain. Other systemic sites such as adrenal
glands, spleen, pancreas, and ovaries are usually not
detected until autopsy.
28–30 PR in HCC is uncommon. The
reported incidence ranged 2–16%.
11–14,31 In our series, the
PR rate was 3.0%. The rate of unresectable PR was 1.9%,
while another 1.1% underwent resection of PR after liver
resection.
Because PRs after hepatectomy for HCC are rare, many
previous reports related to PRs were included in studies
focusing on extrahepatic recurrences. In comparison, our
study solely examined the risk factors of PR in the cohort
of patients. Cha et al. from Memorial Sloan-Kettering
Cancer Center reported that tumor size of [5 cm and
presence of vascular invasion were signiﬁcant predictors of
extrahepatic recurrences in HCC after resection. These two
factors were similarly found to be signiﬁcant predictors for
PR in our cohort. Furthermore, a positive resection margins
was not found to be a signiﬁcant factor as a result of its low
frequency in their study.
32 In contrast, we found that
positive resection margin was a signiﬁcant predictor of PR,
whereas presence or portal vein/hepatic vein invasion was
not. Furthermore, the presence of bile duct invasion was
found to increase the risk of PR in our study. In terms of
the pattern of distribution of PR, we noted that the omen-
tum was the most common site (47.2%), followed by the
posterior peritoneal lining (inclusive of parietal peritoneal
surface of diaphragm). This was consistent with the pattern
observed in the study by Yeh et al., in which omental
nodules constituted 50% of all cases.
23 However, it is
important to emphasize that our series included both
resectable and unresectable PR, whereas Yeh et al. studied
only resected PR patients.
Ruptured tumor has commonly been postulated to
increase the risk of PR in HCC. Most of the reports on
peritoneal metastasis after ruptured HCC were case reports.
Many of the reports note that peritoneal metastases
occurred 8 months after tumor rupture, although some
occurred as early as 3–4 months after ruptured HCC.
33,34
In our study, there were only two patients in the PR group
with a history of ruptured HCC. One of them developed
four isolated peritoneal lesions 1 month after hepatectomy
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2252 A. W. C. Kow et al.and underwent resection of those lesions (because no other
distant metastasis was noted). Another patient developed
seven disseminated peritoneal nodules with multiple
intrahepatic lesions at 6 months after liver resection after
ruptured HCC and was treated conservatively. This differs
greatly from many reports suggesting that a single meta-
static nodule is the most common presentation for PR after
ruptured HCC.
33,34 Shin et al. reported a patient who sur-
vived a long time with recurred HCC after three bouts of
repeated hepatic resection for intrahepatic recurrences and
one bout of right hemicolectomy for an omental recur-
rence.
35 In the current study, ruptured HCC was a
signiﬁcant factor for PR by univariate analysis but did not
show signiﬁcance on multivariate analysis, probably as a
result of the low incidence of ruptured HCC in our cohort
(n = 14, 1.2%).
Tumor markers levels, such as prehepatectomy PIVKA-
II, AFP, and PIVKA-II level at detection of PR, were all
signiﬁcantly higher in patients with unresectable PR. This
could indicate that the higher tumor load and the dissem-
inated nature of the disease could preclude them from
undergoing potentially curative surgical resection of PR.
Indeed, most of the patients with unresectable PR had
concomitant intrahepatic tumor recurrence and/or other
systemic metastases. We also found that patients with
smaller HCC (B50 mm) and lower T stage of tumor at
primary hepatectomy were more likely to undergo
resection of PR. In addition, they also had signiﬁcantly
fewer lesions (median 1.0, range 1.0–4.0) compared to
those resectable disease (median 2.0, range 1.0–7.0). In this
regard, Yeh and Chen reported that tumor capsule invasion
and elevated AFP level [400 ng/ml were signiﬁcant pre-
dictors of peritoneal implantation after hepatectomy.
13
Reports on the long-term survival outcome of patients
with peritoneal metastasis after hepatectomy are scarce in
the literature, leading to a lack of recommendations in the
management of PR in HCC. In general, when PR occurs in
HCC, surgical resection with curative intent would not be
considered. In one rare report of 20 year data by Lin et al.,
patients with metachronous peritoneal metastasis experi-
enced a median survival of 12.5 months—signiﬁcantly
longer than those who did not undergo PR resection
(2.1 months).
14 In addition, Nakayama et al. reported that
resection of peritoneal metastases arising from HCC is
justiﬁed because patients experienced disease-free survival
and OS of 11.8 to 81.6 months after salvage therapy.
12 In
our series, the median OS for resected PR was
33.0 months, which was signiﬁcantly longer than patients
with unresectable PR (median OS 15.0 months). The
5 year survival for resectable PR was 48.0%, compared to
6.0% in patients with unresectable PR.
Some patients with PR after resection of HCC may
experience good long-term survival if the peritoneal
metastasis was resected. In the current study, in addition to
TABLE 5 Univariate and multivariate analyses of overall survival in patients with PR
Factor Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
PR resectable 0.207 0.069–0.621 0.005* 0.042 0.007–0.262 0.001*
Prehepatectomy AFP[400 ng/dl 3.232 1.353–7.721 0.008* 0.458 0.067–3.120 0.425
Prehepatic PIVKA-II[200 mAU/ml 2.124 0.805–5.604 0.128
HCC size[50 mm 2.645 1.142–6.126 0.023* 0.819 0.150–4.482 0.818
Edmonson grade III and IV 5.759 1.151–28.808 0.033* 0.156 0.023–1.041 0.055
Stratiﬁed T stage of HCC (III and IV) 1.882 0.795–4.456 0.150
Microvascular invasion 2.157 0.721–6.452 0.169
Portal vein invasion 2.344 0.845–6.500 0.102
Bile duct invasion 1.603 0.533–4.826 0.401
Serosal involvement 22.271 3.054–162.407 0.002* 25.616 2.436–269.313 0.007*
Positive resection margin 3.870 0.790–18.953 0.095
Interval between hepatectomy and PR[6 mo 0.181 0.064–0.514 0.001* 0.195 0.041–0.922 0.039*
AFP at detection of PR[200 ng/dl 1.884 0.927–3.829 0.008* 11.321 1.766–72.581 0.010*
PIVKA-II at detection of PR[200 mAU/ml 0.852 0.402–1.808 0.677
Single vs. multiple peritoneal lesions 1.996 0.815–4.890 0.131
Omental seeding vs. other locations 0.450 0.184–1.099 0.080
Size of largest peritoneal lesion[30 mm 1.363 0.594–3.125 0.465
Total size of peritoneal lesions[50 mm 1.096 0.482–2.495 0.827
CI conﬁdence interval
* Statistically signiﬁcant at P\0.05
Peritoneal Recurrence in HCC 2253resection of the peritoneal lesions, longer interval between
hepatectomy and detection of PR[6 months was a posi-
tive prognostic factor for OS. On the other hand, presence
of serosal involvement and high AFP levels of[200 ng/dl
at detection of PR were signiﬁcant negative predictors of
survival in PR. Indeed, a long disease-free interval sug-
gested that there was a subset of patients with better tumor
biology, and thus the peritoneal metastasis took a much
longer time to become clinically evident. This group of
patients would certainly experience better long-term sur-
vival after peritoneal metastasectomy. There were a few
long-term survivors in our series with disease-free intervals
of more than 48 months and an OS of more than 5 years.
Two were still alive at the time of last follow-up.
Although resection of HCC was associated with a high
incidence of recurrence, aggressive therapy for the recur-
rence is a key strategy in prolonging survival. On the basis
of our analysis, we strongly recommend that surgical
resection of PR be offered as an option as part of a mul-
timodality therapy in HCC after hepatectomy in selected
patients. Suitable candidates include patients with small
tumor size (HCC B 50 mm), low T stage of tumor, pre-
hepatectomy PIVKA-II level of \200 mg/dl, low AFP
level at detection of PR (\200 ng/dl), and long interval
between hepatectomy and PR ([6 months).
Finally, we acknowledge that the retrospective nature of
this analysis is a limitation of the study. The study could
potentially underestimate the real incidence of PR, which
was the reason why we reviewed such a large series of
patients and went through their post-HCC resection scans
in such detail. Further prospective studies would result in a
better understanding of this condition. However, we rec-
ognize that this would be a difﬁcult task because of the low
incidence of PR in HCC.
In conclusion, peritoneal metastases of HCC are rare.
Risk factors that we identiﬁed as predictors of PR after
hepatectomy for HCC included tumor size [50 mm,
presence of MVI, bile duct invasion, and positive resection
margins. Selected patients with small tumor size
(HCC B 50 mm), low T stage of tumor, prehepatectomy
TABLE 6 Information on resected PR
Patient
no.
Details of resected PR No. of
lesions
Size of
largest
lesion (mm)
Total size of
lesions
(mm)
Interval between
hepatectomy and PR
(month)
Overall
survival
(month)
Survival
status
Further
recurrent
peritoneal
lesions
1 Peritoneal mass, abdominal
wall nodule and subxiphoid
mass
4 40 125 9 10 Alive No
2 Peritoneal mass and omentum 4 50 86 1 3 Dead Yes, resected
chest wall
lesion
3 Omentum, splenic hilum at
lesser curve
3 50 130 19 33 Dead Yes, not
resectable
4 Lesser sac, caudate lobe and 3 35 70 2 6 Alive Yes, resected
peritoneal
lesion
5 Right upper quadrant mass and
right chest wall
2 50 100 18 45 Alive Yes, not
resectable
6 Omentum and diaphragmatic
nodule
2 35 58 48 102 Alive No
7 Subdiaphragmatic mass with
en bloc resection of
diaphragm
1 23 23 102 115 Dead No
8 Abdominal wall mass 1 15 15 52 71 Alive No
9 Right-sided abdominal wall
mass
1 10 10 19 42 Alive No
10 Peritoneal nodule 1 12 12 6 23 Alive No
11 Abdominal wall at rectus
abdominis
1 21 21 6 22 Dead No
12 Anterior aspect of duodenum
and peritoneum on head of
pancreas
1 60 60 6 27 Dead Yes, not
resectable
13 Metastasis to SB and sigmoid
colon
1 140 140 11 16 Alive Yes, not
resectable
2254 A. W. C. Kow et al.PIVKA-II level\200 mg/dl, low AFP level at detection of
PR (\200 ng/dl), and long interval between hepatectomy
and resected PR ([6 months) would be suitable candidates
for resection of PR.
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